# Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

> **NCT07235033** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Uncomplicated Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** KAE609
- **DRUG:** SoC (Coartem)
- **DRUG:** KLU156

## Key facts

- **NCT ID:** NCT07235033
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-23
- **Primary completion:** 2025-03-05
- **Final completion:** 2025-03-19
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07235033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07235033, "Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07235033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*